An in vitro biological model for evaluation of the anti-dandruff performance of hair care products was established. In this model, Malasseziafurfur(M.furfur) was used as indicator bacteria with pigskin as substrate.Th...An in vitro biological model for evaluation of the anti-dandruff performance of hair care products was established. In this model, Malasseziafurfur(M.furfur) was used as indicator bacteria with pigskin as substrate.This model functions in following steps: pretreatment for the substrate; inoculation of indicator bacteria;measuring the bacteriostatic efficacy by the contact plates after washing the pigskin with the sample shampoo;calculation of the effective index P; evaluation of the anti-dandruff performance by the effective index P. Three kinds of anti-dandruff agents including BPT, ZPT and OCT were tested by the model. Results showed that the order for antibacterial efficacy of the anti-dandruff agents within the mass fraction range of 0.1 %~2.0% was BPT>ZPT>OCT. Results of the evaluation on each type of shampoo showed that: one displays no antidandruff efficacy; three displays medium anti-dandruff efficacy; two displays strong anti-dandruff efficacy.展开更多
目的:评价和分析维泊妥珠单抗上市后的药物不良反应(adverse drug reaction,ADR)信号,为临床安全性管理提供参考。方法:通过开放性OpenVigil数据平台,收集2019年6月10日(美国FDA批准上市时间)至2023年3月31日美国FDA不良事件报告系统(FA...目的:评价和分析维泊妥珠单抗上市后的药物不良反应(adverse drug reaction,ADR)信号,为临床安全性管理提供参考。方法:通过开放性OpenVigil数据平台,收集2019年6月10日(美国FDA批准上市时间)至2023年3月31日美国FDA不良事件报告系统(FAERS)数据库中维泊妥珠单抗的ADR报告。采用比例失衡法中的报告比值比(ROR)和比例报告比(PRR)进行信号挖掘。为提高阈值,得到信号较强、较常出现的ADR,将信号进行二次筛选。结果:共检索到维泊妥珠单抗相关ADR报告2408份,经过二次筛选得到83个ADR信号。其中,脊柱磁共振成像异常、骨吸收增加、骨质溶解、天门冬氨酸氨基转移酶降低、丙氨酸氨基转移酶降低、低纤维蛋白原血症、肺栓塞等26个ADR信号在药品说明书中未提及。信号数或累积例数较多的系统器官分类包含感染及侵染类疾病(24个信号、632例),各类检查(17个信号、675例),血液及淋巴系统疾病(11个信号、734例),各类神经系统疾病(7个信号、153例),免疫系统疾病(3个信号、95例),全身性疾病及给药部位各种反应(2个信号、145例),代谢及营养类疾病(2个信号、87例)等。结论:除说明书提示的常见ADR外,本研究发现了维泊妥珠单抗新的ADR风险信号。建议临床在关注感染、骨髓抑制、周围神经病、输液相关反应、肝功能异常等已知常见ADR的同时,予以脊柱磁共振成像异常、骨吸收增加等新的风险信号更多关注。展开更多
文摘目的:主观评价和客观评估不同成像参数下CBCT的图像质量,分析图像质量的主观评价和客观评价间的关系。方法:分别采用6台不同品牌CBCT扫描仪〔3D Accuitomo(Morita)、i-CAT(Kavo)、5G(NewTom)、Smart3D(北京朗视)、DCT Pro(Vatech)、VGi(NewTom)〕,在各个品牌的典型曝光条件下(电压和电流强度不同)扫描空间分辨率模体和高仿真头模,7位医师对拍摄的CBCT图像进行主观评价打分,比较不同CBCT扫描仪的空间分辨率和对常见口腔解剖结构的可见性。客观评价指标采用各仪器所获的图像空间分辩率(LP/mm)。结果:7位医师的组内一致性和组间一致性均无显著性差异。主观评价New Tom 5G为2分,i-CAT为5分,其余4个品牌匀为4分,客观评价i-CAT的LP/mm为1.8,Smart3D为2.0,其余4个品牌为1.0~1.7。在相同管电流条件下,不同管电压的图像主观质量有显著性差异。在相同管电压条件下,不同管电流的图像主观质量有显著性差异。结论:图像质量的主客观评价具有一定的一致性,不同品牌之间的客观评价差异可能与电压、电流强度不同有关。
文摘An in vitro biological model for evaluation of the anti-dandruff performance of hair care products was established. In this model, Malasseziafurfur(M.furfur) was used as indicator bacteria with pigskin as substrate.This model functions in following steps: pretreatment for the substrate; inoculation of indicator bacteria;measuring the bacteriostatic efficacy by the contact plates after washing the pigskin with the sample shampoo;calculation of the effective index P; evaluation of the anti-dandruff performance by the effective index P. Three kinds of anti-dandruff agents including BPT, ZPT and OCT were tested by the model. Results showed that the order for antibacterial efficacy of the anti-dandruff agents within the mass fraction range of 0.1 %~2.0% was BPT>ZPT>OCT. Results of the evaluation on each type of shampoo showed that: one displays no antidandruff efficacy; three displays medium anti-dandruff efficacy; two displays strong anti-dandruff efficacy.
文摘目的:评价和分析维泊妥珠单抗上市后的药物不良反应(adverse drug reaction,ADR)信号,为临床安全性管理提供参考。方法:通过开放性OpenVigil数据平台,收集2019年6月10日(美国FDA批准上市时间)至2023年3月31日美国FDA不良事件报告系统(FAERS)数据库中维泊妥珠单抗的ADR报告。采用比例失衡法中的报告比值比(ROR)和比例报告比(PRR)进行信号挖掘。为提高阈值,得到信号较强、较常出现的ADR,将信号进行二次筛选。结果:共检索到维泊妥珠单抗相关ADR报告2408份,经过二次筛选得到83个ADR信号。其中,脊柱磁共振成像异常、骨吸收增加、骨质溶解、天门冬氨酸氨基转移酶降低、丙氨酸氨基转移酶降低、低纤维蛋白原血症、肺栓塞等26个ADR信号在药品说明书中未提及。信号数或累积例数较多的系统器官分类包含感染及侵染类疾病(24个信号、632例),各类检查(17个信号、675例),血液及淋巴系统疾病(11个信号、734例),各类神经系统疾病(7个信号、153例),免疫系统疾病(3个信号、95例),全身性疾病及给药部位各种反应(2个信号、145例),代谢及营养类疾病(2个信号、87例)等。结论:除说明书提示的常见ADR外,本研究发现了维泊妥珠单抗新的ADR风险信号。建议临床在关注感染、骨髓抑制、周围神经病、输液相关反应、肝功能异常等已知常见ADR的同时,予以脊柱磁共振成像异常、骨吸收增加等新的风险信号更多关注。